Stock Scorecard
Stock Summary for ImmunityBio Inc (IBRX) - $5.36 as of 11/20/2024 4:11:58 PM EST
Total Score
2 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IBRX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IBRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IBRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for IBRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for IBRX (24 out of 90)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for IBRX
Financial Details for IBRX
Company Overview |
|
|---|---|
| Ticker | IBRX |
| Company Name | ImmunityBio Inc |
| Country | USA |
| Description | ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 5.36 |
| Price 4 Years Ago | 13.33 |
| Last Day Price Updated | 11/20/2024 4:11:58 PM EST |
| Last Day Volume | 5,014,599 |
| Average Daily Volume | 7,746,015 |
| 52-Week High | 10.53 |
| 52-Week Low | 3.10 |
| Last Price to 52 Week Low | 72.90% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 120.49 |
| Sector PE | 40.32 |
| 5-Year Average PE | -7.64 |
| Free Cash Flow Ratio | 28.21 |
| Industry Free Cash Flow Ratio | 15.59 |
| Sector Free Cash Flow Ratio | 27.97 |
| Current Ratio Most Recent Quarter | 2.68 |
| Total Cash Per Share | 0.19 |
| Book Value Per Share Most Recent Quarter | -1.07 |
| Price to Book Ratio | 0.00 |
| Industry Price to Book Ratio | 5.50 |
| Sector Price to Book Ratio | 20.88 |
| Price to Sales Ratio Twelve Trailing Months | 508.46 |
| Industry Price to Sales Ratio Twelve Trailing Months | 20.11 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 696,831,000 |
| Market Capitalization | 3,735,014,160 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -40.00% |
| Reported EPS 12 Trailing Months | -0.90 |
| Reported EPS Past Year | -0.52 |
| Reported EPS Prior Year | -1.13 |
| Net Income Twelve Trailing Months | -587,794,000 |
| Net Income Past Year | -583,196,000 |
| Net Income Prior Year | -416,567,000 |
| Quarterly Revenue Growth YOY | 7,346.00% |
| 5-Year Revenue Growth | 67.62% |
| Operating Margin Twelve Trailing Months | -13.14 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 130,367,000 |
| Total Cash Past Year | 266,462,000 |
| Total Cash Prior Year | 107,184,000 |
| Net Cash Position Most Recent Quarter | -842,408,000 |
| Net Cash Position Past Year | -570,490,000 |
| Long Term Debt Past Year | 836,952,000 |
| Long Term Debt Prior Year | 673,172,000 |
| Total Debt Most Recent Quarter | 972,775,000 |
| Equity to Debt Ratio Past Year | -2.35 |
| Equity to Debt Ratio Most Recent Quarter | -3.27 |
| Total Stockholder Equity Past Year | -586,987,000 |
| Total Stockholder Equity Prior Year | -447,327,000 |
| Total Stockholder Equity Most Recent Quarter | -745,148,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -434,095,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.62 |
| Free Cash Flow Past Year | -397,341,000 |
| Free Cash Flow Prior Year | -436,900,000 |
Options |
|
| Put/Call Ratio | 0.79 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.23 |
| MACD Signal | 0.35 |
| 20-Day Bollinger Lower Band | 2.67 |
| 20-Day Bollinger Middle Band | 4.51 |
| 20-Day Bollinger Upper Band | 6.35 |
| Beta | -0.43 |
| RSI | 46.27 |
| 50-Day SMA | 5.14 |
| 150-Day SMA | 4.31 |
| 200-Day SMA | 7.01 |
System |
|
| Modified | 11/21/2024 3:25:34 AM EST |